Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer''s disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Latest shares articles
An unprecedented signal just triggered on the US Dollar
The US dollar just collapsed against the Taiwanese new dollar, with the pairing falling 8% in just a few days, crashing below this key support line and reaching its lowest level in over a year.
19 hours ago
Trading Gold’s short-term bull channel
Denial of Fed Chair Powell’s removal has meant a pullback off the highs, but what will it take to get gold prices to break out of its short-term bull channel?
07:23, 17 July 2025
Nasdaq 100: Trading US CPI
Futures up on Nvidia’s China sales resumption of AI chips, but the next test is US pricing data.
06:29, 15 July 2025
Cocoa price prediction: Third-party target
Read our cocoa price forecast for 2025 and beyond, with insights from third-party analysts and commodities market experts.
15:58, 14 July 2025
Ratings and Reviews
Ratings and Reviews
